Coexistence of MACC1 and NM23-H1 dysregulation and tumor budding promise early prognostic evidence for recurrence risk of early-stage colon cancer.

Ozturk E., AKSOY S., UĞRAŞ N., TUNCA B., Ceylan S., Tezcan G., ...Daha Fazla

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, cilt.126, sa.2, ss.99-108, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 126 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/apm.12801
  • Dergi Adı: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.99-108
  • Anahtar Kelimeler: colon cancer, early stage, metastasis-associated colon cancer-1, NME/NM23 nucleoside diphosphate kinase 1, tumor budding, EPITHELIAL-MESENCHYMAL TRANSITION, TGF-BETA, COLORECTAL-CANCER, CELL-MIGRATION, EXPRESSION, GENE, PROGRESSION, METASTASIS, INVASION, MET
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

The tumor-node-metastasis (TNM) classification, the presence of a mucinous component, and signet ring cells are well-known criteria for identifying patients at a high risk for recurrence and determining the therapeutic approach for early-stage colon cancer (eCC). Nevertheless, recurrence can unexpectedly occur in some eCC cases after surgical resection. The aims of the present study were to evaluate the relation of dysregulated MACC1, c-MET, and NM23-H1 expression with the histopathological features of tumors in recurrence formation in eCC cases. A total of 100 sporadic eCC patients without poor prognosis factors were evaluated in this study. The relationship between the altered expression of MACC1, c-MET, and NM23-H1 and pathological microenvironmental features, including the presence of tumor budding and desmoplasia, were assessed. The primary outcomes, including 5-year overall survival (OS) and disease-free survival (DFS), were also measured. Compared with nonrecurrent patients, the expression level of MACC1 was 8.27-fold higher, and NM23-H1 was 11.36-fold lower in patients with recurrence during the 5-year follow-up (p = 0.0345 and p=0.0301, respectively). In addition, the coexistence of high MACC1 and low NM23-H1 expression and tumor budding was associated with short OS (p < 0.001). We suggest that the combination of reduced NM23-H1, induced MACC1, and the presence of tumor budding are promising biomarkers for the prediction of recurrence and may aid the stratification of patients with stage II colon cancer for adjuvant chemotherapy.